Figure 2.

Role of CD36 and GPR120 in LA-mediated MAPK activation in hTBCs. A) hTBCs were pretreated with SSO (20 µM, 30 min) before addition of LA for 5 or 10 min. B) CD36 and GPR120 levels in control (c; solvent treated) or LA (20 µM)-treated TBC lysates. C) Western blot analysis of phosphorylated (p) MEK1/2, ERK1/2 and ELK in control (c) or cells treated with 20 µM LA, 20 µM GA, or both 20 µM LA and 20 µM GA. Data are representative of 3–5 independent experiments.